Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain

PLoS Biol. 2017 Mar 21;15(3):e2001882. doi: 10.1371/journal.pbio.2001882. eCollection 2017 Mar.

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating the levels of plasma low-density lipoprotein cholesterol (LDL-C). Here, we demonstrate that the compound PF-06446846 inhibits translation of PCSK9 by inducing the ribosome to stall around codon 34, mediated by the sequence of the nascent chain within the exit tunnel. We further show that PF-06446846 reduces plasma PCSK9 and total cholesterol levels in rats following oral dosing. Using ribosome profiling, we demonstrate that PF-06446846 is highly selective for the inhibition of PCSK9 translation. The mechanism of action employed by PF-06446846 reveals a previously unexpected tunability of the human ribosome that allows small molecules to specifically block translation of individual transcripts.

Publication types

  • Validation Study

MeSH terms

  • Animals
  • Cell Line
  • Cell-Free System
  • Cholesterol / blood
  • Escherichia coli / genetics
  • HeLa Cells
  • Heterocyclic Compounds, 4 or More Rings / pharmacology
  • Humans
  • Male
  • Mass Spectrometry
  • Molecular Targeted Therapy
  • Proprotein Convertase 9 / blood
  • Proprotein Convertase 9 / genetics
  • Protein Biosynthesis / drug effects*
  • Protein Biosynthesis / physiology
  • Rabbits
  • Rats
  • Rats, Sprague-Dawley
  • Ribosomes / drug effects*
  • Ribosomes / metabolism
  • Ribosomes / physiology

Substances

  • Heterocyclic Compounds, 4 or More Rings
  • PF-06446846
  • Cholesterol
  • PCSK9 protein, human
  • Proprotein Convertase 9